| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2796191 | Diabetes Research and Clinical Practice | 2015 | 4 Pages |
Abstract
•Lobeglitazone is a novel PPAR-γ agonist containing the TZD motif.•Lobeglitazone is mainly excreted in feces, thereby reducing the risk of bladder cancer.•Lobeglitazone showed a favorable balance of efficacy and safety in patients with type 2 diabetes during 52 weeks.
We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Sun Hwa Kim, Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi,